Results 151 to 160 of about 5,574 (244)

Key Regulatory Considerations for the Development of Biosimilar Pharmaceutical Products

IOSR Journal of Pharmacy (IOSRPHR), 2014
openaire   +1 more source

Performance evaluation of an adalimumab biosimilar autoinjector and its reference device: comparative use human factors study in patients with rheumatoid arthritis and juvenile idiopathic arthritis. [PDF]

Drug Deliv
Moses K S, Konda Ramachary Subramanian S.   +1 more
europepmc   +1 more source

Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics <i>vs</i> biosimilars. [PDF]

World J Gastroenterol
Moura CS, Etingin A, Lukusa L, Singh H, Narula N, Targownik LE, Leung Y, Zezos P, Polewiczowska-Nowak B, Afif W, Bernatsky S.   +10 more
europepmc   +1 more source

The Impact of Biosimilar Launch on Molecule Price and Pharmaceutical Expense: The Case of the Insulin Glargine in Italy [PDF]

Value in Health, 2017
A Tettamanti, L Cioni, C Tucci
openaire   +1 more source

Correction: Effect of liraglutide biosimilar vs. reference liraglutide on weight reduction in T2DM patients with obesity: post hoc analysis of phase III trial. [PDF]

Cardiovasc Diabetol Endocrinol Rep
Ghosh S, Sethi B, Kalra S, Baruah MP, Mane A, Choudhari S, Petare A, Jadhav M, Patil S, Barkate H.   +9 more
europepmc   +1 more source

Toward Regulatory Convergence and Streamlined Biosimilar Development: Recommendations from an International Qualitative Study. [PDF]

BioDrugs
Car E, Barbier L, Schwarzenberger I, Huys I, Simoens S, Vulto AG.   +5 more
europepmc   +1 more source

Drugs anticipated to be selected for Medicare price negotiation in 2026 for implementation in 2028. [PDF]

J Manag Care Spec Pharm
Cousin EM, Martin K, Hansen RN, Coster J, Sullivan SD.   +4 more
europepmc   +1 more source

Evaluation of a New Potential Bevacizumab Biosimilar in Corneal Neovascularization. [PDF]

Turk J Ophthalmol
Özgür A, Yeşilırmak N, İnan MA, Bağrıaçık EÜ, Özmen MC.   +4 more
europepmc   +1 more source

Switching From Intravitreal Ranibizumab (Lucentis) to Biosimilar Ranibizumab (Ongavia) Injections: Insights From a Tertiary Care Eye Centre. [PDF]

Cureus
Sourla E, Zaheer N, Chavan R.
europepmc   +1 more source

Biosimilar Versus Innovator Ranibizumab in Myopic CNVM: Comparative Real-World Outcomes- The BRIM Study. [PDF]

Clin Ophthalmol
Chakraborty D, Sinha TK, Sinha S, Biswas RK, Maiti A, Nandi K, Rungta D, Bhattacharya R.   +7 more
europepmc   +1 more source